Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Special Drug Use Investigation for Eylea for Retinopathy of Prematurity (ROP)

NCT05705258 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT05705258
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05705258 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Special Drug Use Investigation for Eylea for Retinopathy of Prematurity (ROP)
Lead sponsor
Bayer
Phase
Observational
Overall status
Active, not recruiting
Start date
March 27, 2023
Completion date
March 30, 2027
Enrollment
75 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

infants, newborns, retinopathy of prematurity